These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 36159861)

  • 1. Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy.
    Liu Z; Liu X; Shen H; Xu X; Zhao X; Fu R
    Front Immunol; 2022; 13():978377. PubMed ID: 36159861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
    Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
    Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
    Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
    Front Immunol; 2019; 10():925. PubMed ID: 31244820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD39/CD73/A2AR pathway and cancer immunotherapy.
    Xia C; Yin S; To KKW; Fu L
    Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches.
    Thompson EA; Powell JD
    Annu Rev Med; 2021 Jan; 72():331-348. PubMed ID: 32903139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine in cancer immunotherapy: Taking off on a new plane.
    Zhang C; Wang K; Wang H
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
    Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting adenosine and regulatory T cells in cancer immunotherapy.
    Churov A; Zhulai G
    Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.
    Sek K; Mølck C; Stewart GD; Kats L; Darcy PK; Beavis PA
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting adenosine for cancer immunotherapy.
    Leone RD; Emens LA
    J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.
    Klepsch V; Hermann-Kleiter N; Baier G
    Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for cancer treatment.
    Donátová K; Nováková E; Šupolíková M
    Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosinergic signaling as a target for natural killer cell immunotherapy.
    Wang J; Matosevic S
    J Mol Med (Berl); 2018 Sep; 96(9):903-913. PubMed ID: 30069747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.